首页> 外文会议>World congress of the International Photodynamic Association >Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer
【24h】

Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer

机译:光动力疗法(PDT)和高剂量率近距离放射疗法(HDR)联合治疗阻塞性支气管内非小细胞肺癌的结果

获取原文

摘要

Introduction: We reviewed the outcome of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) for patients with symptomatic obstruction from endobronchial non-small cell lung cancer. Methods: Nine patients who received combined PDT and HDR for endobronchial cancers were identified and their charts reviewed. The patients were eight males and one female aged 52-73 at diagnosis, initially presenting with various stages of disease: stage IA (N=1), stage IIA (N=1), stage III (N=6), and stage IV (N=1). Intervention was with HDR (500 cGy to 5 mm once weekly for 3 weeks) and PDT (2 mg/kg Photofrin?, followed by 200 J/cm~2 illumination 48 hours post infusion). Treatment group 1 (TG-1, N=7) received HDR first; Treatment group 2 (TG-2, N=2) received PDT first. Patients were followed by regular bronchoscopies. Results: Treatments were well tolerated, all patients completed therapy, and none were lost to follow-up. In TG-1, local tumor control was achieved in six of seven patients for: 3 months (until death), 15 months, 2+ years (until death), 2+ years (ongoing), and 5+ years (ongoing, N=2). In TG-2, local control was achieved in only one patient, for 84 days. Morbidities included: stenosis and/or other reversible benign local tissue reactions (N=8); photosensitivity reaction (N=2), and self-limited pleural effusion (N=2). Conclusions: Combined HDR/PDT treatment for endobronchial tumors is well tolerated and can achieve prolonged local control with acceptable morbidity when PDT follows HDR and when the spacing between treatments is one month or less. This treatment regimen should be studied in a larger patient population.
机译:简介:我们回顾了联合光动力疗法(PDT)和高剂量率近距离放射疗法(HDR)对支气管内非小细胞肺癌有症状性阻塞的患者的治疗效果。方法:确定9例接受了PDT和HDR联合治疗的支气管内癌患者,并对其图表进行了回顾。患者在诊断时为八位男性,一位女性,年龄在52-73岁,最初表现出疾病的不同阶段:IA期(N = 1),IIA期(N = 1),III期(N = 6)和IV期(N = 1)。干预措施为HDR(500 cGy至5 mm,每周一次,连续3周)和PDT(2 mg / kg Photofrin ?,然后在输注后48小时以200 J / cm〜2的光照)进行干预。第1治疗组(TG-1,N = 7)首先接受HDR治疗;治疗组2(TG-2,N = 2)首先接受PDT。患者接受常规支气管镜检查。结果:治疗耐受性良好,所有患者均已完成治疗,且未丢失任何随访药物。在TG-1中,在7名患者中有6名实现了局部肿瘤控制:3个月(直到死亡),15个月,2年以上(直到死亡),2年以上(进行中)和5年以上(进行中,N) = 2)。在TG-2中,只有一名患者进行了84天的局部控制。发病率包括:狭窄和/或其他可逆的良性局部组织反应(N = 8);光敏反应(N = 2)和自限性胸腔积液(N = 2)。结论:HDR / PDT联合治疗支气管内肿瘤的耐受性良好,当PDT遵循HDR且治疗间隔为一个月或更短时,可以实现长期局部控制,并具有可接受的发病率。这种治疗方案应在更大的患者人群中进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号